C

CITY THERAPEUTICS, INC.

CTYFiled

CITY THERAPEUTICS, INC. · Nasdaq Global Market · latest filing 2026-09-24

Report source
One-minute decisionBASIC RESEARCHSource completeness · 38%

Preliminary IPO remains materially incomplete, with price, share count, proceeds and timing blank.

As of the September 24, 2026 S-1, City Therapeutics proposed a Nasdaq CTY IPO but had not supplied core pricing and size terms.

Where does the money go?Awaiting verificationS-1 · 2026-09-24
Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointRegistration statement effectiveness and subsequent pricing are not dated in the supplied evidence.S-1 · 2026-09-24

Capital destination

Awaiting verification

S-1 · 2026-09-24

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1 ↗
Next checkRegistration statement effectiveness and subsequent pricing are not dated in the supplied evidence.
Latest filing2026-09-24

Capital destination

Awaiting verification

S-1 · 2026-09-24

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1 ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

StatusReference
Awaiting verificationSource ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · S-1 ↗

Holder data awaits verification

The filing identifies major investors and conversion-based holdings, but the supplied excerpts omit complete ownership, economic and voting totals. · 2026-09-24

The filing identifies major investors and conversion-based holdings, but the supplied excerpts omit complete ownership, economic and voting totals.

One disclosed holder; not a complete ownership distribution.Check the source · S-1 ↗

Conditional lock-up timeline

StatusReference
Awaiting verificationSource ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

No product candidate has established safety, efficacy or regulatory approval; preclinical results may not predict clinical results.

Potential impact
Awaiting verification
Monitor
Registration statement effectiveness and subsequent pricing are not dated in the supplied evidence.
Evidence
BUSINESS ↗
SEC EDGAR

S-1

2026-09-24

Open SEC filing ↗